Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutic Pipeline Program, 2015
    Orexin Receptor Modulators for the Treatment of Circadian Sleep-wake Disorders in Parkinson's Disease

    Study Rationale:
    Reset Therapeutics, Inc. (Reset) will develop a new therapy to address excessive daytime sleepiness, a common non-motor symptom in Parkinson’s disease (PD). The natural daily rhythm of...

  • Access to Data and Biospecimens, 2015
    14-3-3 Phosphorylation as a Biomarker of Parkinson’s Disease Supplement

    Study Rationale:                   
    Disruption of 14-3-3s protein is implicated in Parkinson’s disease (PD). Recently, we observed that 14-3-3 phosphorylation — a chemical modification of 14-3-3s — is...

  • Target Validation, 2015
    Anti-inflammatory Role of Activin-A in Protection against Alpha-synuclein-mediated Pathology

    Objective/Rationale:             
    Neuroinflammation is essential for the pathogenesis and progressionof Parkinson’s disease (PD); therefore, the identification of immunosuppressive agents that can...

  • Improved Biomarkers and Clinical Outcome Measures, 2015
    Eye Tracking as a Biomarker for Manifest and Prodromal Parkinson’s Disease

    Study Rationale:                   
    Over the past 14 years, we have utilized sophisticated commercial eye movement monitoring equipment to collect data from over 3300 participants. Our work aims to...

  • Therapeutic Pipeline Program, 2015
    Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson Disease

    Study Rationale:
    Gait and balance problems, particularly falls, are common and disabling symptoms in Parkinson disease (PD), and do not improve markedly with existing treatments. Studies have indicated...

  • Target Validation, 2015
    Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression

    Study Rationale:                             
    A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.